How many units of Crystagen should I draw?

It depends on your vial size, BAC water, and dose. For a 20mg vial with 0mL BAC water, a beginner dose of 10mg is typically 0 units on a U-100 syringe. Use the calculator above for your exact numbers.

How much BAC water should I add to Crystagen?

The standard amount is 0mL of bacteriostatic water for a 20mg vial. More water gives a more dilute solution — easier to measure small doses. Less water means fewer injections per vial. Adjust the BAC water slider in the calculator to see how it changes your syringe units.

How long does a Crystagen vial last?

At a beginner dose of 10mg daily, a 20mg vial lasts about 2000 doses. The calculator shows exact doses per vial for your selected tier.

What syringe should I use for Crystagen?

Most people use a U-100 insulin syringe (1mL / 100 units). For very small doses, a U-50 or U-30 syringe gives better precision. The calculator adjusts units automatically for whichever syringe you pick.

Crystagen Dosage Calculator

ImmuneOralResearch~0.5-2 hours half-life

Crystagen is a synthetic tripeptide (Glu-Asp-Pro, molecular weight ~345 Da) developed through the Khavinson peptide bioregulator program at the St.

Supports T-cell and B-cell population balance in preclinical immune modelsPreserved thymic architecture in gamma-irradiated animal modelsActivated proliferation of human thymic epithelial cells in vitroNormalized immunogram parameters in approximately 82% of elderly patients in a Russian clinical observation4 weeks on / 12 weeks off

Vial Size

BAC Water (mL)

Dosing Level

10mcg · Daily

Custom Dose (mcg) — optional

Syringe Type

0.0 units

100 units (1mL)

Concentration

mcg/mL

Draw Volume

< 0.001

Syringe Units

< 0.1

units

Doses / Vial

doses

Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.

Cycle Planner

Cycle Length (weeks)

Price Per Vial ($) — optional

Oral. Typical beginner frequency: daily.

Crystagen Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~0.5-2 hours (estimated, ultrashort peptide)

After 1 half-life (4h): 50% remainsAfter 2 half-lives (7h): 25% remainsAfter 3 half-lives (11h): 12.5% remains

At a 20mcg dose: 50% = 10mcg remaining after 4h. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Crystagen Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	10mg	Daily
Moderate	20mg	Daily
Aggressive	20mg	2x Daily

Note: Crystagen (Glu-Asp-Pro) is a synthetic tripeptide derived from the Khavinson peptide bioregulator program, designed to mirror immunomodulatory fractions isolated from Thymalin. Typical courses run 10-30 days and are repeated 2-3 times per year. Take capsules 15-20 minutes before meals.

About Crystagen

Crystagen is a synthetic tripeptide (Glu-Asp-Pro, molecular weight ~345 Da) developed through the Khavinson peptide bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It was isolated as one of several bioactive fractions from Thymalin, a polypeptide thymus extract that's been approved in Russian clinical practice since 1982. The peptide targets immune system regulation, specifically T-cell and B-cell populations and thymic epithelial cell activity. In preclinical studies using gamma-irradiated rat models, Crystagen preserved the cortex-medulla architectural division of the thymus, maintained thymocyte proliferation, and increased macrophage and mast cell counts. In elderly patients, oral Crystagen administration contributed to normalization of the immunogram in approximately 82% of cases, according to a Russian clinical report. The peptide also promotes heterochromatinization of chromatin in blood lymphocytes from elderly subjects. In vitro, it activates proliferation of human thymic epithelial cells and inhibits proliferation of K-562 human erythromyelosis tumor cells. Most Crystagen research comes from a single research group, and the peptide hasn't undergone independent Western clinical trials.

View full Crystagenguide →Add to schedule →